Results 211 to 220 of about 6,598 (226)

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Lancet Respiratory Medicine,the, 2021
Damian G Downey, Manu Jain, David J Pasta   +2 more
exaly  

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older – The RECOVER Trial

American Journal of Respiratory and Critical Care Medicine, 2023
Paul McNally
exaly  

Effect of elexacaftor/tezacaftor/ivacaftor on airway and systemic inflammation in cystic fibrosis

Thorax, 2023
Tomás P Carroll, Mark P Murphy
exaly  

Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy

Journal of Cystic Fibrosis, 2022
David C Young, Brian Bourque
exaly  

Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis

Journal of Cystic Fibrosis, 2022
Lena Wucherpfennig, Simon M F Triphan, Hans-Ulrich Kauczor   +2 more
exaly  

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Pharmaceutics, 2022
Eva Choong, Angela Koutsokera
exaly  

Impact of elexacaftor–tezacaftor–ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis

Pediatric Pulmonology, 2023
Shahid I Sheikh, Karen McCoy
exaly  

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Lancet, The, 2019
Edward F Mckone, Damian G Downey, Eva Van Braeckel   +2 more
exaly  

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

New England Journal of Medicine, 2019
Peter Gordon Middleton, Marcus A Mall, Larry C Lands   +2 more
exaly  

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

New England Journal of Medicine, 2017
Anne Munck, Edward F Mckone, Cornelis K Van Der Ent   +2 more
exaly